Evidence map›Paper›PMID 42439924›Full record

ArticleSurgery today2026

The post-neoadjuvant absolute lymphocyte count reflects the pathological response and local tumor control in pancreatic cancer.

Ryo Saito, Hidetake Amemiya, Wataru Izumo, Taishu Oka, Suguru Maruyama, Koichi Takiguchi, Katsutoshi Shoda, Kensuke Shiraishi, Shinji Furuya, Yoshihiko Kawaguchi and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ryo SaitoFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 4093898, Japan. rsaitoh@yamanashi.ac.jp.ORCID http://orcid.org/0000-0003-3125-4671
Hidetake AmemiyaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 4093898, Japan.
Wataru IzumoFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 4093898, Japan.
Taishu OkaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 4093898, Japan.
Suguru MaruyamaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 4093898, Japan.
Koichi TakiguchiFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 4093898, Japan.
Katsutoshi ShodaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 4093898, Japan.
Kensuke ShiraishiFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 4093898, Japan.
Shinji FuruyaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 4093898, Japan.
Yoshihiko KawaguchiFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 4093898, Japan.
Hiromichi KawaidaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 4093898, Japan.
Daisuke IchikawaFirst Department of Surgery, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 4093898, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePredictive markers of the response to neoadjuvant chemotherapy (NAC) in pancreatic cancer are limited. We investigated whether the absolute lymphocyte count (ALC), a surrogate marker of host immune competence, could predict the pathological response to NAC.

methodsThis retrospective single-center study included patients with pancreatic ductal adenocarcinoma who underwent pancreatectomy after NAC (2019 and 2025). The pathological response was classified as good (JPS grade ≥ 2) or poor (grade 1a/1b). Logistic regression was used to identify predictors of a good response. Locoregional recurrence was analyzed using competing risk methods.

resultsAmong the 110 patients, 20 (18.2%) achieved a good pathological response. The Preoperative ALC (measured immediately before surgery) was higher in the good-response group (median 1544 vs. 1053/µL, p = 0.014). In a multivariable analysis, ALC independently predicted a good response (OR per 500/µL, 1.59; 95% CI 1.09-2.32; p = 0.016), whereas CA19-9 was not significant. Patients with a good pathological response had a lower cumulative incidence of locoregional recurrence (3-year: 7.0% vs. 37.6%, p = 0.036).

conclusionsPreoperative ALC predicts the pathological response to NAC and reflects host immune competence relevant to local tumor control. As a simple and widely available biomarker, ALC may aid in the perioperative decision-making for pancreatic cancer.

Indexed as

Absolute lymphocyte countHost immunityNeoadjuvant chemotherapyPancreatic cancerPathological response

Identifiers

PMID42439924

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.